Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
2023 | U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
2023 | U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt | CI |
Financials (USD)
Sales 2021 | 201K | Sales 2022 | 82.05K | Capitalization | 3.05M |
---|---|---|---|---|---|
Net income 2021 | -3M | Net income 2022 | -2M | EV / Sales 2021 | 59.5 x |
Net Debt 2021 | 8.93M | Net Debt 2022 | 10.08M | EV / Sales 2022 | 160 x |
P/E ratio 2021 |
-0.84
x | P/E ratio 2022 |
-0.99
x | Employees | 11 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.05% |
Managers | Title | Age | Since |
---|---|---|---|
Miguel Tomás
CEO | Chief Executive Officer | 58 | 02-12-31 |
Mark Borman
CHM | Chairman | 69 | 09-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Greg Knutson
BRD | Director/Board Member | 72 | 17-03-04 |
Director/Board Member | 100 | 03-05-31 | |
Mark Borman
CHM | Chairman | 69 | 09-04-30 |
1st Jan change | Capi. | |
---|---|---|
0.00% | 661 | |
-0.51% | 103B | |
+3.00% | 96.73B | |
+1.66% | 21.31B | |
-16.34% | 21.21B | |
-6.82% | 18.79B | |
-41.41% | 16.37B | |
-23.02% | 13.68B | |
+6.44% | 13.44B | |
+24.01% | 10.98B |
- Stock Market
- Equities
- USRM Stock